Fusion Antibodies plc (AIM:FAB)
London · Delayed Price · Currency is GBP · Price in GBX 15.75
-1.25 (-7.35%)
Oct 3, 2025, 5:24 PM GMT+1
Fusion Antibodies Revenue
In the fiscal year ending March 31, 2025, Fusion Antibodies had annual revenue of 1.97M GBP with 72.98% growth. Fusion Antibodies had revenue of 758.00K in the half year ending March 31, 2025, a decrease of -26.97%.
Revenue
1.97M
Revenue Growth
+72.98%
P/S Ratio
9.11
Revenue / Employee
81.88K
Employees
24
Market Cap
17.90M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.97M | 829.00K | 72.98% |
| Mar 31, 2024 | 1.14M | -1.77M | -60.84% |
| Mar 31, 2023 | 2.90M | -1.90M | -39.55% |
| Mar 31, 2022 | 4.80M | 634.00K | 15.22% |
| Mar 31, 2021 | 4.17M | 270.00K | 6.93% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 41.24B |
| GSK plc | 31.63B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| ConvaTec Group | 1.72B |
| Hikma Pharmaceuticals | 2.35B |
| HUTCHMED (China) | 439.54M |
| Genus | 672.80M |